Evidence map›Paper›PMID 30887071›Full record

ArticleDer Internist2019

[Chronic fibrosing lung diseases : Idiopathic pulmonary fibrosis from the perspective of its differential diagnosis].

R C Dartsch, L Fink, A Breithecker, P Markart, S Tello, W Seeger, A Günther

Abstract read
PubMed Publisher
In one paragraph

Article in Der Internist, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

R C DartschAbteilung für Innere Medizin, Justus-Liebig-Universität Gießen, Gießen, Deutschland.
L FinkUniversities of Giessen and Marburg Lung Center (UGMLC), Deutsches Zentrum für Lungenforschung (DZL), Justus-Liebig-Universität Gießen, Klinikstr. 36, 35392, Gießen, Deutschland.
A BreitheckerAbteilung für diagnostische und interventionelle Radiologie, Justus-Liebig-Universität Gießen, Gießen, Deutschland.
P MarkartAbteilung für Innere Medizin, Justus-Liebig-Universität Gießen, Gießen, Deutschland.
S TelloAbteilung für Innere Medizin, Justus-Liebig-Universität Gießen, Gießen, Deutschland.
W SeegerAbteilung für Innere Medizin, Justus-Liebig-Universität Gießen, Gießen, Deutschland.
A GüntherAbteilung für Innere Medizin, Justus-Liebig-Universität Gießen, Gießen, Deutschland. andreas.guenther@innere.med.uni-giessen.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fibrosing lung diseases describe a heterogeneous group of interstitial lung diseases (ILD) of highly variable etiology, but with a unifying terminal process of irreversible, fibroproliterative destruction of the alveolar surface, loss of compliance and progressive impairment of gas exchange. In view of the heterogeneity, the disastrous prognoses in some cases and the treatment consequences, a thorough differential diagnosis is essential in all patients. Antifibrotic therapies are currently only indicated in idiopathic pulmonary fibrosis (IPF). The only curative therapeutic option is lung transplantation. Therefore, suitable patients should be promptly evaluated.

Indexed as

Diagnosis, DifferentialHumansIdiopathic Pulmonary FibrosisLungLung Diseases, InterstitialPrognosisPulmonary FibrosisTomography, X-Ray ComputedAlveolitis, extrinsic allergicComputed tomography, high-resolutionDisease managementLung diseases, interstitialLung transplantation

Identifiers

PMID30887071

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.